AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03525028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The investigators assumed that the combination therapy of metformin and glucocorticoids can decrease glucocorticoids side effects and synergia the anti-inflammatory and immune inhibitory effect of glucocorticoids. So the investigators use metformin in the experimental group.
Study NCT03525028 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigators use placebo in the control group.
Study NCT02523235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ropivacaine 0.2%
Description: Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
Study NCT02523235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine 0.2%
Description: Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
Study NCT02968667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowerment
Description: 6 weeks of empowerment program and supported face to face discussion
Study NCT00911209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietitian counselling
Description: Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP + comfort feature A
Description: Auto CPAP + comfort feature A using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP with comfort feature B
Description: Auto CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP with no comfort feature
Description: Auto CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Auto CPAP with comfort feature A+B
Description: Auto CPAP with comfort feature A+B using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with comfort feature A
Description: CPAP with comfort feature A using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with comfort feature B
Description: CPAP with comfort feature B using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with no comfort feature
Description: CPAP with no comfort feature using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP with comfort feature A + B
Description: CPAP with comfort feature A + B using Fisher \& Paykel Healthcare CPAP Device
Study NCT02948010 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP at Sub therapeutic level
Description: CPAP at Sub therapeutic level using Fisher \& Paykel Healthcare CPAP Device
Study NCT03308318 — intervention group
Intervention type: PROCEDURE
Intervention: The supratemporalis approach
Description: The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
Study NCT02543892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PATH-wSP
Description: Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
Study NCT02543892 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study NCT00633776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: formoterol fumarate
Description: Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
Study NCT00633776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol fumarate
Description: Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
Study NCT01484093 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
Description: INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
Study NCT03772977 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Health Champion
Description: A health coach embedded within an existing clinical care team
Study NCT03764228 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hAECs
Description: Human amniotic epithelial cells（hAECs）
Study NCT01707251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ibuprofen
Description: 800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
Study NCT01707251 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Placebo control
Study NCT03315988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adoption of a vegan diet
Description: Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
Study NCT05452837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FDFG
Description: FDFG is applied to the parotidectomy bed after superficial parotidectomy
Study NCT05452837 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMAS
Description: SMAS flap is applied to the parotidectomy bed after superficial parotidectomy
Study NCT00387907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: larotaxel (XRP9881)
Description: administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
Study NCT00387907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: administered as a 90-minute IV infusion on Day 1 of every week (qw)
Study NCT02811393 — intervention group
Intervention type: OTHER
Intervention: Assess muscle function
Description: Assess muscle function with hand grip test and sit and stand test
Study NCT02212483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: First home intervention with advice
Description: A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
Study NCT02212483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: First home intervention without any advice
Description: A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
Study NCT02212483 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Final home visit
Description: Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices.
Study NCT02212483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Final home visit
Description: Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices.
Study NCT02212483 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Final home visit
Description: Final home visit at the end of the study after 12 months, with sampling and home audit.~For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices.
Study NCT01284387 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001 (vanutide cridificar)
Description: Comparisons of 2 different doses of ACC-001 or placebo for 24 months
Study NCT03031574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUVN-D4010
Description: Tablets
Study NCT04777669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Noise Reduction
Description: In within subject design, listeners will have background noise removed by a noise reduction algorithm
Study NCT04611737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviewing
Description: Self-Determination Theory within motivational interviewing
Study NCT01823640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT01823640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Rhinovirus strain 16 (HRV-16)
Description: 100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
Study NCT00578318 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing Active
Description: Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
Study NCT00578318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Active
Description: Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
Study NCT03556540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: physical exercise
Description: Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
Study NCT03556540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise
Description: Each participant will perform 30 minutes of aerobic physical activity, using cycle ergometer. The exercise will begin 30 minutes after the start of hemodialysis.
Study NCT03545321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOON+
Description: MOON+ is an intervention to support the pharmacy and pharmacist to improve opioid safety and naloxone provision. Materials include educational trainings, materials for use with pharmacists, information for patients, and materials for standardizing overdose safety at the pharmacy
Study NCT00475735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0249
Description: MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
Study NCT00475735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concerta (methylphenidate)
Description: Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
Study NCT00475735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
Study NCT03336073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
Study NCT03336073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: carfilzomib at a dose of 70 mg/m2 (20 mg/m2 only in the first infusion) intravenously (iv) on days 1, 8, and 15
Study NCT03336073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: dexamethasone oral at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16
Study NCT03336073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: dexamethasone oral at a dose of 20 mg (10 mg for patients >75 years) days 1, 2, 8, 9, 15 and 16
Study NCT03336073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide at a dose of 300 mg/m2 iv on days 1, 8 and 15
Study NCT02681445 — intervention group
Intervention type: DEVICE
Intervention: Breath Collection
Description: breath will be collected from patients in breath bag for analysis for observational study.
Study NCT02503072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Small lottery prizes based on adherence
Description: Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
Study NCT02503072 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Small lottery prizes based on timely clinic visits
Description: Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
Study NCT02910570 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide 3 mg (Saxenda)
Description: Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
Study NCT02910570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide 3 mg placebo
Description: Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
Study NCT04336462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen
Description: Hydrogen-Oxygen Generator with Nebulizer Model: AMS-H-03 Gas production: 2.0 L/min, 2.5 L/min, and 3 L/min, three gears in total (in this study, the gas production of each machine is 3 L/min, two sets are connected and used together by three-way connection, and the total gas production is 6 L/min.) Manufacturer: Shanghai Asclepius Meditech Co., Ltd.
Study NCT04336462 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: oxygen inhaled,3 L/min . 6 hour a day.
Study NCT02457832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Tango Dancing
Description: Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
Study NCT02457832 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Control (BC) Condition
Description: Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
Study NCT02865759 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfetalness
Description: The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
Study NCT03106935 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1-2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
Study NCT00715728 — intervention group
Intervention type: DEVICE
Intervention: Intraoperative warming with Bair Hugger forced air system
Description: Intraoperative warming with Bair Hugger forced air system
Study NCT00141908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-alpha Hydroxyprogesterone Caproate
Description: 250 mg IM weekly
Study NCT00141908 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Castor oil
Description: weekly IM injections
Study NCT04148521 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Health - Virtual Patient Navigation
Description: Patients are identified by a clinician in the ED as needing psychiatric evaluation and a referral is made to a tele-psych provider for a virtual consult. Patients can be enrolled to the intervention arm based on a randomization scheme that randomly allocates days that navigators are available. The psychiatrist will make a recommendation to admit or discharge the patient. For patients that have a discharge recommendation on days that BH-VPN is available, patients will be offered the BH-VPN program. Enrolled patients are followed for up to 45 days. On days where the navigator is available, all patients who meet eligibility criteria will be considered exposed to the intervention.
Study NCT01644825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: 80 mg/m2 IV days 1, 8, 15 every 28 days
Study NCT01644825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 80 mg/m2 IV days 1, 8, 15 every 28 days
Study NCT01644825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: orally, 800 mg orally daily
Study NCT01245335 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMAC injection
Description: Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
Study NCT01245335 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Injection of placebo into ischemic tissue of the lower extremity
Study NCT00629551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saredutant (SR48968)
Description: oral administration,capsules
Study NCT00715728 — intervention group
Intervention type: DEVICE
Intervention: Intraoperative warming with Hotdog resistive heating system
Description: Intraoperative warming with Hotdog resistive heating system
Study NCT00629551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paroxetine
Description: oral administration, capsules
Study NCT00629551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paroxetine
Description: oral administration, capsules
Study NCT00629551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: oral administration, capsules
Study NCT00629551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration, capsules
Study NCT01329185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valganciclovir
Description: Valganciclovir 450mg twice a day for 14 days prior to transplant date
Study NCT01329185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule twice a day for 14 days prior to transplant date
Study NCT01527903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion
Description: IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
Study NCT01527903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam infusion
Description: midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
Study NCT00212797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 34517
Description: low dose Org 34517
Study NCT00212797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 34517
Description: high dose Org 34517
Study NCT00212797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo